RxDoctor Payments Data

Karrah de la Fuente, PA

Physician Assistant · Arlington, TXNPI 1518389980

Payments from drug & device makers

$7,583in general payments, 2019–2025

Across 404 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$932
  • Lilly USA, LLC$928
  • GSK$877
  • AbbVie$684
  • AstraZeneca$675
  • Boehringer Ingelheim$343
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,571100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,583 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$28,545
Medicare patients
89
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,589
JardianceEmpagliflozin26$28,909
MounjaroTirzepatide27$27,066
EliquisApixaban18$13,933
XareltoRivaroxaban13$9,601
Spiriva HandihalerTiotropium Bromide12$6,240
Aripiprazole15$4,993
SymbicortBudesonide/Formoterol Fumarate13$4,189
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,938
Levothyroxine Sodium137$1,575
Atorvastatin Calcium182$1,340
Albuterol Sulfate HfaAlbuterol Sulfate46$1,160
Pantoprazole Sodium97$1,104
Omeprazole52$1,091
Fluticasone Propionate43$1,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$877$29,58931 claims
Boehringer IngelheimJardiance$343$28,90926 claims
Lilly USA, LLCMounjaro$928$27,06627 claims
PfizerEliquis$328$13,93318 claims
Johnson & JohnsonXarelto$87$9,60113 claims
AstraZenecaSymbicort$675$4,18913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →